Mesoporous silicate nanoparticles/3D nanofibrous scaffold-mediated dual-drug delivery for bone tissue engineering

• Published in: Journal of controlled release 2018-06, Vol.279, p.69-78
• Main Authors: Yao, Qingqing, Liu, Yangxi, Selvaratnam, Balaranjan, Koodali, Ranjit T., Sun, Hongli
• Format: Article
• Language: English
• Subjects: Angiogenesis; Animals; Bone and Bones - metabolism; Bone Morphogenetic Protein 2 - administration & dosage; Cell Differentiation; Chitosan - chemistry; Deferoxamine; Deferoxamine - administration & dosage; Drug Delivery Systems; Drug Liberation; Dual release system; Gelatin - chemistry; Humans; Mesenchymal Stem Cells - metabolism; Mesoporous silicate nanoparticles; Mice; Nanofibers; Nanofibrous scaffold; Nanoparticles; Osteogenesis; Osteogenesis - physiology; Porosity; Silicates - chemistry; Time Factors; Tissue Engineering - methods
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2018.04.011

Controlled delivery systems play a critical role in the success of bone morphogenetic proteins (i.e., BMP2 and BMP7) for challenged bone repair. Instead of single-drug release that is currently and commonly prevalent, dual-drug delivery strategies are highly desired to achieve effective bone regeneration because natural bone repair process is driven by multiple factors. Particularly, angiogenesis is essential for osteogenesis and requires more than just one factor (e.g., Vascular Endothelial Growth Factor, VEGF). Therefore, we developed a novel mesoporous silicate nanoparticles (MSNs) incorporated-3D nanofibrous gelatin (GF) scaffold for dual-delivery of BMP2 and deferoxamine (DFO). DFO is a hypoxia-mimetic drug that can activate hypoxia-inducible factor-1 alpha (HIF-1α), and trigger subsequent angiogenesis. Sustained BMP2 release system was achieved through encapsulation into large-pored MSNs, while the relative short-term release of DFO was engineered through covalent conjugation with chitosan to reduce its cytotoxicity and elongate its half-life. Both MSNs and DFO were incorporated onto a porous 3D GF scaffold to serve as a biomimetic osteogenic microenvironment. Our data indicated that DFO and BMP2 were released from a scaffold at different release rates (10 vs 28 days) yet maintained their angiogenic and osteogenic ability, respectively. Importantly, our data indicated that the released DFO significantly improved BMP2-induced osteogenic differentiation where the dose/duration was important for its effects in both mouse and human stem cell models. Thus, we developed a novel and tunable MSNs/GF 3D scaffold-mediated dual-drug delivery system and studied the potential application of the both FDA-approved DFO and BMP2 for bone tissue engineering. [Display omitted]